scinai.com - SCNI Company Value to Revenue

The enterprise value-to-revenue ratio for Scinai Immunotherapeutics (SCNI) demonstrates the impact of the proprietary NanoAb platform for creating affordable inhaled medications. Alpaca antibody technology enables non-invasive lung treatment, while the modernization of bioreactors ensures the fulfillment of R&D contracts. The 2493.46 indicator expresses the state of the metric, helping to distinguish random price spikes from a genuine restructuring of business capital.
BiondVax Pharmaceuticals - analytical breakdowns and key metrics (SCNI)

The success of Scinai Immunotherapeutics (SCNI) depends on the efficiency of developing innovative nanobodies, making revenue a key value driver. By analyzing the EV/Sales chart, an investor assesses the ratio of enterprise value (market capitalization and net debt) to sales, which allows for the determination of the market premium paid per unit of revenue and confirms the company's resilience regardless of macroeconomic fluctuations.